A carregar...
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for many patients due to infusion-related adverse events (AEs), an increased risk of renal toxicity and the inconvenience of regular hospital visits. The use of oral bisphosphon...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2004
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2409647/ https://ncbi.nlm.nih.gov/pubmed/15026791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601663 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|